copenlu/druid huggingface dataset:
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2015-11-15): Aimed at lowering treatment cost of cancer and cardio-vascular diseases that are on the rise in India, Union Health Minister J P Nadda today launched the country's first AMRIT outlet at AIIMS here to sell drugs at highly discounted rates. "Under the AMRIT (Affordable Medicines and Reliable Implants for Treatment) programme, we want to give medicines at an affordable cost. We have identified 202 drugs of cancer and cardio-vascular diseases where the price is going to be reduced on an average by 60 to 90 per cent. [...] "The AMRIT pharmacy would be dispensing drugs and implants based on valid prescriptions from respective doctors. Prices of some drugs available at AMRIT pharmacy are strikingly low. For example, AMRIT will sell 'Docetaxel 120mg' used for chemotherapy cycle at Rs 888.75 (93 per cent rebate) for one cycle whereas MRP of the injection is Rs 13,440.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2024-01-31): The Amrit pharmacies in SECL hospitals will ensure availability of generic and lifesaving branded drugs under one roof. These pharmacies will provide medicines, implants, surgical consumables etc. for common diseases as well as critical conditions, at highly subsidized rates which will greatly benefit in and outpatients consisting of SECL employees as well as the general public visiting these hospitals. With medicines being directly supplied to the employees through the Amrit pharmacies, the initiative will also help in reducing medical reimbursements thereby helping the company with judicious use of medical resources while ensuring quality medicines to the patients. Launched in 2015, AMRIT ( Affordable Medicines and Reliable Implants for Treatment) is a flagship scheme of the Ministry of Health and Family Welfare to provide medicines for various diseases including critical illness like cancer and cardiovascular diseases at highly subsidized rates to the public. Currently there are more than 300 Amrit pharmacies being operated different States/UTs in the country.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2015-11-14): Home / India News / 'Amrit' outlet in AIIMS to provide affordable drugs for cancer and heart diseases 'Amrit' outlet in AIIMS to provide affordable drugs for cancer and heart diseases [...] Government of India owned HLL Lifecare Ltd (HLL) will establish and run Amrit Pharmacy, which will sell both drugs and implants at significant discount on market rates, based on authentic prescriptions from doctors. "To begin with, HLL will dispense 195 oncology drugs, 186 cardiovascular drugs and 148 cardiac implants through Amrit pharmacy," HLL Chairman and Managing Director Dr. M. Ayyappan said here today.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2015-11-15): The pharmacy named AMRIT -- Affordable Medicines and Reliable Implants for Treatment -- will have 202 drugs of cancer and cardiovascular diseases where the price is going to be reduced on an average by 60 to 90 per cent. "Under the AMRIT programme, we want to give medicines at an affordable cost. We have identified 202 drugs of cancer and cardio-vascular diseases where the price is going to reduced on an average by 60 to 90 per cent. In the same way, 148 cardiac implants will be given from the centre and sold here and their cost will be reduced by 50 to 60 per cent," Mr Nadda said on the occasion. [...] "Some of the prices of the AMRIT Pharmacy drugs are strikingly low such as Amrit will sell 'Docetaxel 120mg' used for chemotherapy cycle at Rs.888.75 (93 per cent rebate) for one cycle, when the MRP of the injection is Rs.13,440. Similarly, Caboplatin 450 mg would be sold at Rs.1,316.25 while its MRP is Rs 2,561.57," said AIIMS Director MC Misra.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2017-08-23): AMRIT pharmacy outlets which is a revolutionary step towards giving relief to the common man will provide 164 medicines (branded drugs) for cancer, 191 for cardio-vascular diseases and 5,200 other Non Communicable Diseases (NCDs) are now being given at 50-90 per cent less price to the patient. [...] India’s first pharmacy retail store came into being at the All India Institute of Medical Sciences (AIIMS) that will provide drugs for cancer and cardiovascular diseases at a 60 to 90 per cent discount on prevailing market rates. The pharmacy which is branded AMRIT (Affordable Medicines and Reliable Implants for Treatment), will also provide cardiac implants that will be sold at 50 to 60 per cent discount. [...] The chief minister, who along with Nadda also laid the foundation stone of Super Speciality block of IGMC Complex to be constructed at Chamyana, 20 km from Shimla said, "AMRIT Pharmacy outlet in IGMC campus will provide medicines at 70 to 90 per cent cheaper rates. "The launch of this would be a major relief for the patients who cannot afford costly medicines for treatment of cancer, cardiac and other diseases. This will also enable the patients to purchase medicines under one roof."
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2019-12-11): In order to reduce out-of-pocket expenditure for the consumers, the Union Health Ministry has established a total of 172 Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies across 20 states and 3 Union Territories (UTs) in the country to make available and accessible branded drugs, implants, surgicals and disposables at affordable prices.AMRIT retail outlets are opened in partnership with both central government and state government medical institutions. Rolled out pan- India in 2015, AMRIT pharmacies sell branded drugs such as those used for treating cancer and cardiovascular diseases at average discounts of up to 60% of MRP. Unlike Jan Aushadhi stores, which are run by the Union Ministry of Chemicals and Fertilisers, AMRIT stores do not sell generic drugs.AMRIT retail pharmacy network offers more than 5,200 drugs, implants, surgical disposables and other consumables. It offers availability of generic and lifesaving branded drugs under one roof.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2014-05-27): Hence, with the aim to reduce the expenditure incurred by patients on treatment of cancer and heart diseases, the Ministry for Health & Family Welfare, has launched the Affordable Medicines and Reliable Implants for Treatment (AMRIT) programme. As part of the programme, retail outlets will sell drugs for the cancer and heart diseases at highly discounted rates. The AMRIT pharmacy would be selling 202 cancer and 186 cardio-vascular drugs, and 148 types of cardiac implants at very affordable prices. Patients can buy medicines and implants at 50 to 60 percent cheaper prices than the open market from AMRIT outlet. The project has been floated in a tie-up with government-owned HLL Lifecare Ltd (HLL) which is deputed to establish and run the AMRIT chain of pharmacies across the country.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2024-10-09): AMRIT a good strategy for affordable cancer drugs. The news on "most recent cancer drugs offer few benefits" pictured the need for rationale use of cancer drugs that was already available in affordable cost and stressed on the fact of new cancer drugs approved by USFDA that was available with high prices in India with meager efficacy. This is also true in all government set up in India. All those new cancer drugs approved by USFDA fit their role in mostly in corporate hospital than government institution catering service for the cancer patients. Here a note on AMRIT (affordable medicines and reliable implants for treatment) is to be mentioned. It was for two non communicable diseases namely cancer and cardiovascular system. Under the AMRIT (Affordable Medicines and Reliable Implants for Treatment) programme medicines will be provided at an affordable cost. More than 195 drugs for treatment of cancer are dispensed. For example1, AMRIT will sell anticancer drug ‘Docetaxel 120mg' used for chemotherapy cycle at Rs 888.75 (93 %) for one cycle whereas Maximum retail price of the injection is Rs 13,440. Similarly, another 'Caboplatin 450mg’ sold at Rs 1,316.25 (50%) of its MRP. More than 1.77 lakhs patients have been benefitted2. This has resulted in saving of around Rs 13 crores out of pocket expenditure to the patients (average discount of 69 percent on MRP). The government is planning to open 300 outlets of AMRIT pharmacy in the country with the aim to reduce the expenditure incurred by common patients on treatment of cancer and heart diseases2.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2015-11-26): Discount pharmacies in India will reduce financial burden on patients [...] Two pharmacy units that will dispense drugs for heart diseases and cancer at highly discounted rates have been inaugurated at the All India Institute of Medical Sciences (AIIMS).1 At these Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies, patients will soon be able to purchase about 186 cardiovascular drugs, 148 types of …
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2020-11-20): Union Ministry of Health & Family Welfare has opened country’s first Affordable Medicines and Reliable Implants for Treatment (AMRIT) outlet at AIIMS in New Delhi to sell drugs at highly discounted rates. [...] Key facts - The pilot AMRIT outlet will provide drugs for cancer and cardiovascular diseases at highly discounted rates. - At this outlet the prices of 202 cancer and 186 cardio-vascular drugs will reduced on an average by 60 to 90 per cent.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2019-04-10): The third claim is that ‘AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent’. As per information shared in the Lok Sabha, AMRIT (Affordable Medicines and Reliable Implants for Treatment) Pharmacies are being opened and operated by M/s.HLL Lifecare Ltd., a Central Public Sector Undertaking (CPSU) of Ministry of Health & Family Welfare, with an objective of providing affordable medicines for treatment of Cancer, Cardiovascular and other diseases, stents, implants, surgical disposables and other consumables, thereby reducing the out of pocket expenses. The first AMRIT pharmacy was opened in November 2015 at AIIMS, New Delhi. [...] Fact: AMRIT pharmacies provide drugs for cancer, cardiovascular and other diseases, stents, implants, surgical disposables and other consumables. The average discount that patients can avail ranges from 50 to 55%. Hence, the claim is FALSE.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2018-05-10): Affordable Medicines And Reliable Implants For Treatment (AMRIT) The AMRIT pharmacies provide drugs for cancer and cardiovascular diseases along with cardiac implants at a 60 to 90 per cent discount on prevailing market rates. - As of now 124 stores have been opened so far across 22 states selling over 5200 drugs (including cardiovascular, cancer, diabetes, stents, etc), implants, surgical disposables and other consumables at significant discount of up to 50 % on market rates.
Claim: AMRIT pharmacies provide drugs for cancer and cardiovascular diseases at a discount of 60 to 90 percent (Govt. of India, 2018-05-26)
Evidence (2015-11-17): Union govt. opens AMRIT outlet for cheap cancer and heart disease drugs at AIIMS: All you need to know AMRIT shop to provide drugs for cancer and heart patients at cheapest rates. [...] - The AMRIT shop will be managed by the government-owned HLL Lifecare Ltd - The drugs would be available not only to the patients at the AIIMS to the ones at other hospitals as well - The price of around 202 drugs of cancer and 186 drugs of cardiovascular diseases has been reduced by 60 to 90 percent - The outlet will sell Docetaxel (120mg), an essential drug used for chemotherapy that originally costs around Rs 13,440, at Rs 888.75 - Another drug Carboplatin (450 mg), a drug used for treating ovarian, lungs and throat cancer, is available at only Rs 1,316.25 whereas its original MRP is Rs 2,561.57 - The shop will also have facilities for cardiac implants. Around 148 types of cardiac implants will be available at the outlet - An official report says that 2.8 million Indians are under threat of having cancer and die within a year. This initiative indeed comes at a very crucial point of time.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2018-05-26): An infographic titled ‘cronyism out, cleanliness in’ is one of the many on the Government’s 48-month achievement portal. This one has four claims about the efforts of the government to end corruption. Here is a fact check of these claims.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2024-04-30): The Administration’s focus on reforming federal permitting has led to real results. Thanks to President Biden’s leadership, the time to complete the most extensive form of environmental review is already coming down: agencies are completing a higher proportion of environmental impact statements in under two years than under the previous Administration. The Biden-Harris Administration is also completing environmental assessments for projects faster than the previous Administration – for example, data from the Department of Transportation show that in the first three years, the Biden-Harris Administration completed environmental assessments in an average of 9.6 months compared to 15.4 months for the same number of projects during the Trump Administration. The Biden-Harris Administration is also expanding the use of categorical exclusions, the fastest form of environmental review, bringing review timelines down from months or years to a matter of weeks for projects that have minimal environmental impacts. For example, over 99.5% of federal highway projects were covered by categorical exclusions in fiscal year 2022, meaning the vast majority of projects are moving forward using these faster reviews. The Administration has also expanded the use of categorical exclusions to expedite permitting in key sectors such as EV charging, broadband, CHIPS manufacturing, and clean energy projects.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2022-07-26): A double-edged sword it is. The government has brought down the time taken to provide environmental clearances for projects from 105 days to close to 75 days, the Lok Sabha was informed on Monday. Responding to a question on the delay in granting clearances to projects, Minister of State for Environment, Forest & Climate Change Ashwini Kumar Choubey told the Parliament that the Central government has been taking several steps to expedite the process of environmental clearances. [...] THE NOD, PROPOSALS "Due to various efforts taken by Government towards streamlining the EC procedure, overall time taken in grant of EC has reduced considerably over the years and it has taken approximately 75 days in the year 2021 against the maximum of 105 days as prescribed in EIA Notification, 2006," he said.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2024-10-08): The court also rejected the contention that TVA was required to examine whether the project would meet climate goals set out in executive orders issued by President Biden. Sierra Club v. Tennessee Valley Authority, No. 3:22-cv-01054 (M.D. Tenn. Sept. 30, 2024) [...] Connecticut Court Upheld Denial of Approvals for Development that Local Agency Found Would Have Adverse Effects on Coastal Resources [...] Two claims were filed against the project’s approval before the Second Environmental Court: the first by a group of 14 residents of the Cerrillos commune, and the second by the Cerrillos Municipality. During the process, the Municipality of Cerrillos withdrew its legal action, as did 13 residents. The withdrawal was due to the project’s public declaration that it would no longer use water to cool the servers. In February 2022, the company presented a "Modification of the ‘Cerrillos Data Center’ Project" to the Environmental Assessment Service (SEA), which involves replacing the water-based cooling towers with air-cooled condensers, thereby eliminating the use of groundwater from the three wells of the Santiago Central Aquifer over which the company has water rights. The action was continued only by one resident.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2023-11-15): As cited in our 2016 blog environmental permitting, once a permit application is submitted, the Environment Agency (EA) aim to have it Duly Made within 12 weeks. If your permit application is Duly Made, it does not mean that you have been granted an environmental permit. Duly Made indicates that the EA have all the necessary information to be able to make a decision on whether or not they will grant you a permit. Then, once your application has been Duly Made, the EA will begin the assessment process. During this time, your permit application will be made available for comment in the public domain. The EA may also need to consult other public bodies to assess whether your permit should be granted and whether there are any significant environmental impacts that will need to be managed. This process can take a further 13 weeks. However, it will take longer if there are extenuating circumstances such as a facility that is of high public interest. [...] Do you think your organisation needs an environmental permit but don’t have the time to put towards completing the application? Please contact Rebecca Chapman or on 0114 272 2270 for further information.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2022-06-14): Yesterday a multi-country flagship workshop on permit-granting processes for renewable energy projects took place. The aim of the workshop was to discuss the options that Member States have in order to accelerate the permitting process, gathering the experience and good practices that have been identified at the Member State level. The event, organised in the framework of a peer-learning tool for environment authorities TAIEX - Environmental Implementation Review, was attended by around 100 high-level officials from Ministries of the Environment, Energy and related Agencies of nearly all EU Member States. It provided an opportunity to discuss challenges and remaining obstacles at national, regional and local levels in the authorisation of renewable energy projects. Experts from Austria, Belgium, Denmark, Finland, Germany and Spain presented good practice examples related to site selection and simplified permitting procedures. Three representatives from the private sector presented examples of minimizing environmental impacts of renewable energy projects. To support Member States in identifying go-to areas for the rapid deployment of new installations for the production of energy from wind and solar renewable sources, Joint Research Centre presented its Energy and Industry Geography Lab – an online platform bringing together a wealth of information on relevant energy, industry and environmental factors. Commission speakers included officials from DG ENV, DG ENER, DG REFORM and JRC.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2022-12-16): MEPs said the maximum period for the approval of new installations will be shortened from 12 months to nine if projects are located in renewable acceleration areas. Outside of such areas, procedures should not take more than 18 months, according to the MEPs. They also said that permits should be granted within six months for capacity upgrades to existing plants. The provisions are expected to go into force in 2023. When designating renewable acceleration zones, member states should try to avoid or reduce negative environmental impacts. Parks and nature reserves, as well as migratory routes for birds and marine mammals, cannot be classified as renewable acceleration zones. MEPs have also established provisions to ensure public consultations before choosing project sites. In addition, the new rules include an obligation for EU countries to ensure that permits to install solar on buildings are issued within three months. For renewable energy installations below 50 kW, notification should suffice. The amendments also state that permitting procedures for storage projects that are co-located with solar should also be expedited, without stating a specific time period.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2024-05-17): The renewable energy industry has been expressing frustration at the lengthy lead times in gaining state and federal environmental and planning approvals for renewable energy projects. Although lead times for projects overall may be lengthy, unpacking where the bottlenecks are and how they relate to environmental approvals is a difficult task. Often these approvals take place alongside parallel processes such as financing and grid connection approvals. So how do we ‘fast-track’ without weakening environmental approvals? The latest Budget provides some potential for positive change. $134.2M was announced for improving approval processes.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2024-06-17): They point to contradictory regulations that at once require farmers to reduce their environmental impact while increasing food production. [...] In a vote held among EU environment ministers today, Finland, Hungary, Italy, the Netherlands, Poland and Sweden rejected the law, while Belgium abstained. [...] Its impacts will be reviewed by the Commission in 2033.
Claim: The time taken for environmental approvals has been brought down to 180 days from 600 days. (Govt. of India, 2018-05-26)
Evidence (2022-04-11): Ironically, a more intense focus on environmental, governance and social (ESG) issues has been accompanied by additional scrutiny to the permitting process, which is adding to these delays. [...] Ensuring project credentials are impeccable is essential for the granting of any permit. [...] A solution may be to move toward a single-touch environmental approvals approach for mining projects, as has been the case in Australia; projects there can now take just two years to start construction.